Tunitas raises $10M in series A

Tunitas Therapeutics Inc. (San Francisco, Calif.) raised $10 million in a series A round co-led by Ally Bridge Group and WuXi Ventures. RA Capital Advisors also participated.

Tunitas develops fusion proteins that target receptors activated by allergens. It is developing lead candidate epsi-gam, a fusion protein comprising the Fc portions of human IgE and IgG1, to treat asthma. CEO Nolan Sigal told BioCentury that Tunitas would start a Phase I trial of the candidate "soon" and that it hopes to begin a Phase IIa trial in 2016. ...